Royalty Pharma RPRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.72M-72.2% | —— | —— | —— | $13.4M0.0% | ||
| $718.23M+20.5% | $827.15M+11.4% | $702.62M-0.1% | $363.98M-44.7% | $596.08M-10.3% | ||
| $4.32M-65.7% | $2.88M-77.1% | $2.88M0.0% | $2.88M0.0% | $12.59M+774% | ||
| $452.37M+42,697% | $733.69M+47.8% | $961.87M-19.5% | $1.11M-99.8% | $1.06M-98.8% | ||
| -$477.87M-195% | -$847.8M-67.7% | -$958.31M+19.7% | -$311.98M+65.1% | $503.92M+682% | ||
| $50.1M-92.9% | $80.54M+53.1% | $146.49M+51.0% | $291.57M+264% | $708.78M— | ||
| $39.88M-25.9% | $40.76M+29.6% | $34.28M+10.5% | $38.61M+25.8% | $53.83M+68.2% | ||
| -$226K— | -$1.79M-178,900% | $0— | $0— | $0— | ||
| -$272.67M+71.0% | -$299.6M— | —— | -$507.81M-144% | -$941.3M-344% | ||
| -$32.3M-120% | -$320.25M— | $307.04M— | -$455.81M-149% | $158.69M-56.6% | ||
| $173.53M+25.0% | $6.68M+730% | $129.99M+64.6% | $796K-0.1% | $138.82M+75.8% | ||
| $3.72M-72.2% | —— | —— | —— | $13.4M0.0% | ||
| $25.5M-49.5% | $50.5M+10,000% | —— | —— | $50.5M— | ||
| $9.7M— | $9.08M— | $1.7M— | $173K— | $0— | ||
| $36.25M-64.4% | $58.24M-19.6% | $34.18M-38.1% | $94.03M+95.7% | $101.7M+68.0% | ||
| $33.62M+5.8% | $29.1M-1.4% | $29.11M-2.4% | $24.05M+3.6% | $31.76M+20.7% | ||
| $915.6M+10.3% | $916.13M+17.8% | $882.36M+11.5% | $726.53M+8.5% | $829.74M+11.4% | ||
| $3.77M+2,032% | $39K-82.8% | $264K-32.3% | $240K-50.6% | $177K-98.7% | ||
| $50M0.0% | $2.71M-89.1% | $0— | $218.6M+337% | $50M— | ||
| $22.5M+408% | $54M— | —— | —— | $4.43M— | ||
| $375K— | $34.72M+40.9% | $0-100% | $0-100% | $0-100% | ||
| $0-100% | —— | —— | —— | $510.55M— | ||
| $4.32M-65.7% | $2.88M-77.1% | $2.88M0.0% | $2.88M0.0% | $12.59M+774% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $104.49M+9.6% | $94.34M+0.7% | $95.31M+1.3% | $93.24M-1.8% | $95.36M+1.7% | ||
| $39.88M-25.9% | $40.76M+29.6% | $34.28M+10.5% | $38.61M+25.8% | $53.83M+68.2% | ||
| $77.97M-7.9% | $79.15M-2.5% | $101.91M+0.3% | $89.22M-2.9% | $84.63M-3.4% | ||
| $0-100% | $0-100% | $15K-98.6% | $4.61M+385% | $1.08M-19.5% | ||
| $0-100% | —— | —— | $219K-0.5% | $220K+150% | ||
| -$226K— | -$1.79M-178,900% | $0— | $0— | $0— | ||
| $6.5M-46.0% | $6.37M-29.5% | $7.25M-56.2% | $8.66M-40.2% | $12.03M+87.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
